Literature DB >> 24200849

Identification of the NAC1-regulated genes in ovarian cancer.

Min Gao1, Ren-Chin Wu2, Alice L Herlinger3, Kailee Yap4, Jung-Won Kim4, Tian-Li Wang5, Ie-Ming Shih6.   

Abstract

Nucleus accumbens-associated protein 1 (NAC1), encoded by the NACC1 gene, is a transcription co-regulator that plays a multifaceted role in promoting tumorigenesis. However, the NAC1-regulated transcriptome has not been comprehensively defined. In this study, we compared the global gene expression profiles of NAC1-overexpressing SKOV3 ovarian cancer cells and NAC1-knockdown SKOV3 cells. We found that NAC1 knockdown was associated with up-regulation of apoptotic genes and down-regulation of genes involved in cell movement, proliferation, Notch signaling, and epithelial-mesenchymal transition. Among NAC1-regulated genes, FOXQ1 was further characterized because it is involved in cell motility and epithelial-mesenchymal transition. NAC1 knockdown decreased FOXQ1 expression and promoter activity. Similarly, inactivation of NAC1 by expression of a dominant-negative construct of NAC1 suppressed FOXQ1 expression. Ectopic expression of NAC1 in NACC1 null cells induced FOXQ1 expression. NAC1 knockdown resulted in decreased cell motility and invasion, whereas constitutive expression of FOXQ1 rescued motility in cells after NAC1 silencing. Moreover, in silico analysis revealed a significant co-up-regulation of NAC1 and FOXQ1 in ovarian carcinoma tissues. On the basis of transcription profiling, we report a group of NAC1-regulated genes that may participate in multiple cancer-related pathways. We further demonstrate that NAC1 is essential and sufficient for activation of FOXQ1 transcription and that the role of NAC1 in cell motility is mediated, at least in part, by FOXQ1.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24200849      PMCID: PMC3873491          DOI: 10.1016/j.ajpath.2013.09.024

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

Review 1.  Notch signaling, gamma-secretase inhibitors, and cancer therapy.

Authors:  Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

2.  Notch3 gene amplification in ovarian cancer.

Authors:  Joon T Park; Mei Li; Kentaro Nakayama; Tsui-Lien Mao; Ben Davidson; Zhen Zhang; Robert J Kurman; Charles G Eberhart; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

3.  A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival.

Authors:  Kentaro Nakayama; Naomi Nakayama; Ben Davidson; Jim J-C Sheu; Natini Jinawath; Antonio Santillan; Ritu Salani; Robert E Bristow; Patrice J Morin; Robert J Kurman; Tian-Li Wang; Ie-Ming Shih
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-27       Impact factor: 11.205

4.  Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis.

Authors:  Shamima Yeasmin; Kentaro Nakayama; Masako Ishibashi; Atsuko Katagiri; Kouji Iida; Indri Nuryani Purwana; Naomi Nakayama; Kohji Miyazaki
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

5.  NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor.

Authors:  Kentaro Nakayama; Naomi Nakayama; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

6.  Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.

Authors:  Ben Davidson; Aasmund Berner; Claes G Trope'; Tian-Li Wang; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2007-03-27       Impact factor: 3.466

7.  A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.

Authors:  Masako Ishibashi; Kentaro Nakayama; Shamima Yeasmin; Atsuko Katagiri; Kouji Iida; Naomi Nakayama; Manabu Fukumoto; Kohji Miyazaki
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  Requirement for the POZ/BTB protein NAC1 in acute but not chronic psychomotor stimulant response.

Authors:  Scott Mackler; Alejandra Pacchioni; Ryan Degnan; Ying Homan; Alana C Conti; Peter Kalivas; Julie A Blendy
Journal:  Behav Brain Res       Date:  2007-09-02       Impact factor: 3.332

9.  Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6.

Authors:  Ping Fu; Julian A Thompson; Leon A Bach
Journal:  J Biol Chem       Date:  2007-05-22       Impact factor: 5.157

10.  ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.

Authors:  Dominico Vigil; Tai Young Kim; Ana Plachco; Andrew J Garton; Linda Castaldo; Jonathan A Pachter; Hanqing Dong; Xin Chen; Brianna Tokar; Sharon L Campbell; Channing J Der
Journal:  Cancer Res       Date:  2012-08-31       Impact factor: 12.701

View more
  12 in total

1.  miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.

Authors:  Xiaoying Wang; Lili Jiang; Qifang Liu
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

2.  Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide.

Authors:  Su-Hyeong Kim; Catherine H Kaschula; Nolan Priedigkeit; Adrian V Lee; Shivendra V Singh
Journal:  J Biol Chem       Date:  2016-04-29       Impact factor: 5.157

3.  miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.

Authors:  Weiwei Shan; Jun Li; Yang Bai; Xin Lu
Journal:  Tumour Biol       Date:  2015-11-09

4.  Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.

Authors:  Yoshinori Tatemichi; Masahiko Shibazaki; Shinji Yasuhira; Shuya Kasai; Hiroshi Tada; Hiroki Oikawa; Yuji Suzuki; Yasuhiro Takikawa; Tomoyuki Masuda; Chihaya Maesawa
Journal:  Cancer Sci       Date:  2015-05-26       Impact factor: 6.716

5.  NAC1 promotes the migration of prostate cancer cells and participates in osteoclastogenesis by negatively regulating IFNβ.

Authors:  Fang Chen; Yinghao Yin; Zhifeng Yan; Ke Cao; Kuangbiao Zhong
Journal:  Oncol Lett       Date:  2017-12-20       Impact factor: 2.967

6.  NAC1 Regulates Somatic Cell Reprogramming by Controlling Zeb1 and E-cadherin Expression.

Authors:  Francesco Faiola; Nuoya Yin; Miguel Fidalgo; Xin Huang; Arven Saunders; Junjun Ding; Diana Guallar; Baoyen Dang; Jianlong Wang
Journal:  Stem Cell Reports       Date:  2017-08-03       Impact factor: 7.765

7.  Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells.

Authors:  Tongfa Ju; Huicheng Jin; Rongchao Ying; Qi Xie; Chunhua Zhou; Daquan Gao
Journal:  Mol Med Rep       Date:  2017-07-14       Impact factor: 2.952

8.  Linc-ROR induces epithelial-to-mesenchymal transition in ovarian cancer by increasing Wnt/β-catenin signaling.

Authors:  Yanhui Lou; Huanhuan Jiang; Zhumei Cui; Lingzhi Wang; Xiangyu Wang; Tian Tian
Journal:  Oncotarget       Date:  2017-07-25

9.  NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells.

Authors:  Min Gao; Alice Laschuk Herlinger; Renchin Wu; Tian-Li Wang; Ie-Ming Shih; Beihua Kong; Leticia Batista Azevedo Rangel; Jin-Ming Yang
Journal:  Aging (Albany NY)       Date:  2020-05-14       Impact factor: 5.682

10.  NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.

Authors:  Kohei Morita; Tomomi Fujii; Hiroe Itami; Tomoko Uchiyama; Tokiko Nakai; Kinta Hatakeyama; Aya Sugimoto; Makito Miyake; Yasushi Nakai; Nobumichi Tanaka; Keiji Shimada; Masaharu Yamazaki; Kiyohide Fujimoto; Chiho Ohbayashi
Journal:  Cancers (Basel)       Date:  2018-09-21       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.